Cargando…

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies

Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell transplantation (HSCT). Despite relatively high incidence, diagnosis and treatment remain a challenge due to non-specific manifestation and li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daraskevicius, Justinas, Petraitis, Vidmantas, Davainis, Linas, Zucenka, Andrius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144376/ https://www.ncbi.nlm.nih.gov/pubmed/35628696 http://dx.doi.org/10.3390/jof8050440

Ejemplares similares

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)

Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study
por: Judickas, Šarūnas, et al.
Publicado: (2021)

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

Efficacy of Antiseptic Solutions in Treatment of Staphylococcus Aureus Infected Surgical Wounds with Patches of Vascular Graft: An Experimental Study in Rats
por: Stanevičiūtė, Elvyra, et al.
Publicado: (2019)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
por: Ghannoum, Mahmoud, et al.
Publicado: (2020)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

Surgery for Pulmonary Fungal Infections Complicating Hematological Malignancies
por: Yamamichi, Takashi, et al.
Publicado: (2018)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
por: Little, Jessica S., et al.
Publicado: (2021)

Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies
por: Salih, Zena, et al.
Publicado: (2013)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
por: Jallow, Sabelle, et al.
Publicado: (2021)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

Epidemiology and clinical manifestation of fungal infection related to Mucormycosis in hematologic malignancies
por: Noorifard, M, et al.
Publicado: (2015)

Invasive Fungal Infections at Presentation of Untreated Hematologic Malignancies: Rare and Elusive
por: Spallone, Amy, et al.
Publicado: (2020)

2557. Development of Rabbit Models of Ventilator-Associated Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Petraitis, Vidmantas, et al.
Publicado: (2023)

Role of Iron and Iron Overload in the Pathogenesis of Invasive Fungal Infections in Patients with Hematological Malignancies
por: Valković, Toni, et al.
Publicado: (2022)

Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?
por: Walsh, Thomas J., et al.
Publicado: (2020)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Human metapneumovirus pneumonia in patients with hematological malignancies
por: Godet, Cendrine, et al.
Publicado: (2014)

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies
por: Gamaletsou, Maria N., et al.
Publicado: (2018)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

Risk Prediction and Prognosis of Invasive Fungal Disease in Hematological Malignancies Patients Complicated with Bloodstream Infections
por: Xiao, Han, et al.
Publicado: (2020)

2100. Epidemiology and Risk Factors for Invasive Fungal Infections Among Patients with Hematological Malignancies In Colombia
por: Ortiz-Martínez, Yeimer, et al.
Publicado: (2022)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Penicillin allergy evaluation in hospitalized patients with hematologic malignancy
por: Patel, Vima M., et al.
Publicado: (2023)

The mortality burden of hematological malignancies in Ecuador
por: Garrido, David, et al.
Publicado: (2021)

Evaluation and Management of Bacterial and Fungal Infections Occurring in Patients with a Hematological Malignancy: A 2011 Update
por: Wade, James C.
Publicado: (2012)

Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients
por: Zimmermann, Philippe, et al.
Publicado: (2022)

Isotopic Niche of Syntopic Granivores in Commercial Orchards and Meadows
por: Balčiauskas, Linas, et al.
Publicado: (2021)

Stable Isotopes Reveal the Dominant Species to Have the Widest Trophic Niche of Three Syntopic Microtus Voles
por: Balčiauskas, Linas, et al.
Publicado: (2021)

2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
por: Bold, Tyler D, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5uhl61lkr34ggl2u1r2dqvv1jg